3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Bolt Biotherapeutics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -169.55%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Bolt Biotherapeutics's 3-Year ROIIC % or its related term are showing as below:
BOLT's 3-Year ROIIC % is ranked worse than 77.95% of 1320
companies
in the Biotechnology industry
Industry Median: -4.42
vs BOLT: -169.55
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Bolt Biotherapeutics 3-Year ROIIC % Related Terms
Bolt Biotherapeutics 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Bolt Biotherapeutics's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOLT vs AIM, ERNA, RVPH: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Bolt Biotherapeutics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bolt Biotherapeutics 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bolt Biotherapeutics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Bolt Biotherapeutics's 3-Year ROIIC % falls into.
Bolt Biotherapeutics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -34.633 (Dec. 2025) - -90.321 (Dec. 2022) )
/
( 31.405 (Dec. 2025) - 64.249 (Dec. 2022) )
=
55.688
/
-32.844
=
-169.55%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Bolt Biotherapeutics (BOLT) has a 3-Year ROIIC % of -169.55 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Bolt Biotherapeutics and its competitors. According to the industry distribution chart, Bolt Biotherapeutics ranks #1029 out of 1320 companies in the Biotechnology industry, placing it in the top 78%.
Is Bolt Biotherapeutics' 3-Year ROIIC % too high?
Bolt Biotherapeutics' current 3-Year ROIIC % is -169.55. Based on the distribution chart, Bolt Biotherapeutics ranks #1029 out of 1320 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Bolt Biotherapeutics has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bolt Biotherapeutics' 3-Year ROIIC % compare to AIM and ERNA?
According to the Biotechnology industry distribution chart, Bolt Biotherapeutics ranks #1029 out of 1320 companies for 3-Year ROIIC %. This places Bolt Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Bolt Biotherapeutics and its competitors. Bolt Biotherapeutics's current 3-Year ROIIC % is -169.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bolt Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Bolt Biotherapeutics (BOLT) is currently considered Possible Value Trap. The stock's GF Value™ is $9.05, compared to a current price of $4.13 — trading 54.4% below its estimated fair value. The current 3-Year ROIIC % is -169.55. Bolt Biotherapeutics' overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Bolt Biotherapeutics (BOLT), the current 3-Year ROIIC % is -169.55 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bolt Biotherapeutics (BOLT) Overvalued in 2026?
Based on GuruFocus' analysis, Bolt Biotherapeutics stock appears to be undervalued.
The current stock price of $4.13 is trading 54.4% below its estimated GF Value™ of $9.05.
GuruFocus considers Bolt Biotherapeutics to be Possible Value Trap.
Key valuation signals for BOLT:
3-Year ROIIC %: -169.55
GF Value™: $9.05 vs. price of $4.13 (54.4% below fair value)
No single metric tells the full story. See the BOLT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
55GF Score
Get the complete analysis for BOLT
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOLT has been successfully added to your 
